The CARE consortium is now closed. This website is no longer updated but will remain available until 31 March 2026

May 24th 2022
CARE paper published in Journal of Medical Virology: Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity

CARE paper published in Journal of Medical Virology: Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity

The CARE partners KU Leuven and Janssen Pharmaceutica NV, in collaboration with The Institute of Medical Virology published a paper reporting on the outcomes from screening a library of antiviral compounds to assess effectiveness against SARS-CoV-2 as part of the emergency response to the pandemic. Although vaccines are currently used to control the COVID-19 pandemic, treatment options are urgently needed for those who cannot be vaccinated and for future coronavirus outbreaks. A high-throughput, high content imaging–based SARS-CoV-2 infection assay was developed and used to screen a library of 5676 compounds that passed Phase 1 clinical trials. Eight drugs were identified as inhibitors of in vitro anti–SARS-CoV-2 activity. However, apart from remdesivir, toxicity and pharmacokinetic data did not support further clinical development of these compounds for COVID-19 treatment.

To learn more, read the paper in the Journal of Medical Virology:: Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures